Active Biotech: Advancing Three Active Projects - Redeye

Redeye revisits its valuation of early-stage biotech company Active after significant progress across its three candidates, but also delays due to Covid-19. At the same time, we believe that the risk has increased slightly in tasquinimod.

Länk till analysen i sin helhet: https://www.redeye.se/research/833516/active-biotech-advancing-three-active-projects?utm_source=finwire&utm_medium=RSS